Picture loading failed.

Anti-TSLP therapeutic antibody (Pre-made Tezepelumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tezepelumab (INN; development codes MEDI9929 and AMG 157) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis. It blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-567-1mg 1mg 3090
GMP-Bios-ab-567-10mg 10mg 21890
GMP-Bios-ab-567-100mg 100mg 148000
GMP-Bios-ab-567-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TSLP therapeutic antibody (Pre-made Tezepelumab biosimilar,Whole mAb)
INN Name Tezepelumab
TargetTSLP
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure5j13:CB
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesAmgen;AstraZeneca;Bispebjerg Hospital;Lund University;MedImmune;University of Copenhagen;University of Newcastle in Australia
Conditions Approvedna
Conditions ActiveAsthma;Atopic dermatitis;Rhinosinusitis;Chronic obstructive pulmonary disease
Conditions Discontinuedna
Development Techna